Avecho Biotechnology Limited

ASX (AUD): Avecho Biotechnology Limited (AVE)

Last Price

0.004

Today's Change

+0.001 (33.33%)

Day's Change

0.004 - 0.004

Trading Volume

15,250,756

Overview

Market Cap

8 Million

Shares Outstanding

2 Billion

Avg Volume

3,637,432

Avg Price (50 Days)

0.00

Avg Price (200 Days)

0.00

PE Ratio

0.00

EPS

0.00

Earnings Announcement

26-Feb-2025

Previous Close

0.00

Open

0.00

Day's Range

0.004 - 0.004

Year Range

0.001 - 0.005

Trading Volume

15,250,756

Price Change Highlight

1 Day Change

33.33%

5 Day Change

100.00%

1 Month Change

33.33%

3 Month Change

60.00%

6 Month Change

33.33%

Ytd Change

33.33%

1 Year Change

33.33%

3 Year Change

-73.33%

5 Year Change

33.33%

10 Year Change

-93.79%

Max Change

-96.59%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment